aluminum sulfate has been researched along with HIV Infections in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allers, C; Aye, PP; Bick, M; Burton, DR; Carnathan, DG; Crotty, S; Dufour, JP; Eskandarzadeh, S; Fahlberg, M; Gao, H; Georgeson, E; Grasperge, BF; Groschel, B; Hangartner, L; Irvine, DJ; Kaczmarek Michaels, K; Kaur, A; Kubitz, M; Lee, WH; Lopez, PG; Maiorino, L; Marina-Zárate, E; Melo, M; Montefiori, DC; Nedellec, R; Ozorowski, G; Pahar, B; Phung, I; Rodrigues, KA; Schief, WR; Schiro, F; Shen, X; Silvestri, G; Torres, JL; Veazey, RS; Ward, AB | 1 |
| Alter, G; Barnett, SW; Bissa, M; Breed, M; Brown, DR; Doster, MN; Franchini, G; Galli, V; Gorini, G; Kramer, J; LaBranche, CC; Liang, F; Liyanage, NPM; Loré, K; Magnanelli, W; Metrinko, M; Montefiori, DC; Pal, R; Phogat, S; Rao, M; Ruprecht, RM; Schifanella, L; Shen, X; Tomaras, GD; Trinh, HV; Vaccari, M; Venzon, DJ; Washington-Parks, R | 1 |
| Abdollahpour-Alitappeh, M; Fathi, M; Khoramabadi, N; Mahdavi, M; Nezamzadeh, R; Yazdi, MH | 1 |
| Faezi, S; Mahdavi, M; Memarnejadian, A; Reza Aghasadeghi, M; Shahosseini, Z; Velashjerdi Farahani, S | 1 |
| Birx, DL; Cox, J; El-Habib, R; Excler, JL; Gilliam, BL; Jagodzinski, LL; Kim, JH; Liu, M; McNeil, JG; Michael, NL; O'Connell, RJ; Paris, R; Polonis, VR; Ratto-Kim, S; Robb, ML; Tomaras, GD; VanCott, TC; Wieczorek, L | 1 |
| Ayres, SL; Connor, RI; Dorosko, SM | 1 |
| Berman, PW; Chernow, M; Francis, DP; Heyward, WL; Hirunras, K; Kaewkangwal, J; Kitayaporn, D; Li, E; Migasena, S; Peterson, ML; Phonrat, B; Pitisuttithum, P; Raktham, S; Sheppard, HW; Shibata, R; Srisuwanvilai, LO; Suntharasamai, P | 1 |
| Berman, PW; Cleland, JL; Eastman, D; Farina, F; Frie, S; Lim, A; Mordenti, J; Nguyen, TT; Peterson, MR; Weissburg, RP | 1 |
2 trial(s) available for aluminum sulfate and HIV Infections
| Article | Year |
|---|---|
Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.
Topics: Adjuvants, Immunologic; Adolescent; Adult; AIDS Vaccines; Alum Compounds; Antibodies, Neutralizing; Female; HIV Antibodies; HIV Antigens; HIV Envelope Protein gp160; HIV Infections; HIV-1; Humans; Immunization; Leukocytes, Mononuclear; Male; Middle Aged; Organophosphorus Compounds; Polymers; Young Adult | 2016 |
Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1.
Topics: Adjuvants, Immunologic; Adolescent; Adult; AIDS Vaccines; Alum Compounds; Female; HIV Antibodies; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Immunization Schedule; Male; Middle Aged; Recombinant Proteins; Substance Abuse, Intravenous; Thailand; Vaccination | 2004 |
6 other study(ies) available for aluminum sulfate and HIV Infections
| Article | Year |
|---|---|
A combined adjuvant approach primes robust germinal center responses and humoral immunity in non-human primates.
Topics: Adjuvants, Immunologic; Animals; Antibodies, Neutralizing; Antigens; env Gene Products, Human Immunodeficiency Virus; Germinal Center; HIV Antibodies; HIV Infections; Immunity, Humoral; Primates | 2023 |
ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type.
Topics: Adjuvants, Immunologic; AIDS Vaccines; Alum Compounds; Animals; Antibodies, Neutralizing; Antibodies, Viral; Female; HIV Infections; Macaca mulatta; SAIDS Vaccines; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Viral Vaccines | 2019 |
Formulation of a recombinant HIV-1 polytope candidate vaccine with naloxone/alum mixture: induction of multi-cytokine responses with a higher regulatory mechanism.
Topics: Adjuvants, Immunologic; AIDS Vaccines; Alum Compounds; Animals; Antibodies, Viral; Drug Compounding; Female; HIV Infections; HIV-1; Humans; Immunization; Interferon-gamma; Interleukins; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Naloxone | 2021 |
Naloxone/alum mixture a potent adjuvant for HIV-1 vaccine: induction of cellular and poly-isotypic humoral immune responses.
Topics: Adjuvants, Immunologic; AIDS Vaccines; Alum Compounds; Animals; Cell Proliferation; Cytokines; Female; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Immunity, Humoral; Immunoglobulin G; Immunoglobulin M; Mice; Mice, Inbred BALB C; Naloxone; nef Gene Products, Human Immunodeficiency Virus; Recombinant Fusion Proteins | 2016 |
Induction of HIV-1 MPR(649-684)-specific IgA and IgG antibodies in caprine colostrum using a peptide-based vaccine.
Topics: Adjuvants, Immunologic; AIDS Vaccines; Alum Compounds; Animals; Colostrum; Female; Goats; HIV Antibodies; HIV Envelope Protein gp41; HIV Infections; HIV-1; Immunoglobulin A; Immunoglobulin G; Infectious Disease Transmission, Vertical; Neutralization Tests; Pregnancy; Vaccines, Subunit | 2008 |
Characterization of the MN gp120 HIV-1 vaccine: antigen binding to alum.
Topics: Adjuvants, Immunologic; Adsorption; AIDS Vaccines; Alum Compounds; Animals; Blood; Catalysis; CHO Cells; Cricetinae; Guinea Pigs; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Male; Papio; Rabbits | 1995 |